Business Description
SAB Biotherapeutics was established in 2014 and operates out of Miami Beach, Florida. The company works to create antibody-based treatments for people living with immune-related conditions and infectious diseases, using a technology that produces human polyclonal antibodies. Its most advanced treatment, SAB-142, is currently being tested in Phase 2b trials as a repeatable therapy aimed at changing the course of type 1 diabetes rather than simply managing its symptoms.
